F.D.A. Panel’s Vote on Peptides Raises Concerns About a Prescribing Boom

The committee endorsed broader use of the peptides in lightly regulated compounding pharmacies that have grown into a multibillion-dollar business.Some F.D.A. scientists pointed out that the peptides under review had not been proven to be safe or effective, and could present risks to patients.